"目錄號(hào): HY-13696
GPCR/G ProteinImmunology/Inflammation-
MSX-122是一種新型小分子CXCR4 拮抗劑, 有效抑制? CXCR4/CXCL12 (IC50值為10 nM)。
相關(guān)產(chǎn)品
Plerixafor octahydrochloride-Reparixin-SCH 527123-Danirixin-SCH 546738-AMD 3465 hexahydrobromide-AMG 487-SB225002-AMD-070 hydrochloride-SCH 563705-NBI-74330-LY2510924-WZ811-IT1t dihydrochloride-SRT3109-
生物活性
Description
MSX-122 is a novel small molecule and partial CXCR4 antagonist,? with potent inhibition of CXCR4/CXCL12 actions (IC50 = 10 nM).IC50 value: 10 nM Target: CXCR4/CXCL12in vitro: MSX-122 is a partial inhibitor of CXCR4/CXCL12 functions. The compelling features of the MSX-122 profile include: (i) potent inhibition of CXCR4/CXCL12 actions (IC50 = 10 nM); (ii) ease of production on a large scale; (iii) effectiveness as an anti-inflammatory and anti-metastatic agent in vivo; and (iv) unique property of blocking homing and recruitment without mobilizing stem cells. MSX-122 blocks invasion and angiogenesis in vitro.in vivo: MSX-122 attenuates colonic damage in mice with experimental colitis.MSX-122 blocks metastasis in an experimental animal model of breast cancer metastasis. MSX-122 blocks metastasis in two more animal models for metastasis.
Clinical Trial
Metastatix, Inc.
Solid Tumors
November 2007
Phase 1
View MoreCollapse
References
